aspirin vs cancer

are you believe taking Aspirin with low dose can prevent for cancer..????

lets read this articel 

Studies in recent years have highlighted the possible benefit of daily aspirin use as a preventive measure against cancer, and new findings suggest it could work as an additional treatment for those who have cancer.

A research team with Oxford University in the United Kingdom, previously found that aspirin reduces the long-term risk of dying from cancer, but the effects do not show up until about eight to 10 years after starting a daily low-dose aspirin regimen. 

The team's latest findings center on aspirin's short-term impact, said lead author Peter Rothwell, MD, PhD, FRCP, of the Nuffield Department of Clinical Neurosciences at Oxford.

The findings show that aspirin reduces the likelihood of metastasis by about 40% to 50%, Rothwell said in comments distributed by the university.

Added to findings in recent years that daily aspirin substantially reduces the long-term risk of some cancers, especially colorectal cancer and esophageal cancer, the results "add to the case for use of aspirin to prevent cancer, particularly if people are at increased risk. Perhaps more importantly, they also raise the distinct possibility that aspirin will be effective as an additional treatment for cancer, to prevent distant spread of the disease."

Rothwell noted that more generally, "no drug has been shown before to prevent distant metastasis, and so these findings should focus future research on this crucial aspect of treatment of patients with cancer that hasn't already spread."

The researchers also reported that the additional risk of stomach bleeds from aspirin use falls with prolonged use. Therefore, Rothwell said, the risks of long-term aspirin treatment, "as might be envisaged to prevent cancer, may well be less than previously thought." The risk of fatal stomach bleeds is not increased compared with placebo. Meanwhile, "the conditions that aspirin helps to prevent," such as cancer, stroke and myocardial infarction, "are much more likely to be disabling or fatal," Rothwell noted.

"Previous analyses of the balance of risk and benefit have simply counted the crude numbers of bleeds and other outcomes, and have not considered the time-course of these risks or the severity of the different types of events."

The findings appear in two separate papers published March 21 on the website of The Lancet and a third paper published on the website of The Lancet Oncology. 

In one paper, researchers examined data from participants in 51 randomized clinical trials comparing the effect of taking aspirin daily with taking no aspirin. The risk of death from cancer decreased 15% in patients taking aspirin daily, and the drop was 37% after five years or more of a daily low-dose regimen. 

Daily low doses also reduced the incidence of cancer after three years by 23% in men and 25% in women.



eIn a second paper, researchers found aspirin reduced metastasis by 36% over the average 6.5-year span of the studies included in the analysis. These effects were independent of age and sex.

In the Lancet Oncology paper, the researchers analyzed observational studies rather than clinical trials. They found a similar reduction in risk in the observational studies.

Rothwell said the data suggest aspirin's effect in preventing metastasis is largest in adenocarcinomas such as colorectal cancer, some cancers of the lung and most cancers of the breast and prostate.

In preventing the longer-term development of new cancers, aspirin seems to have the strongest effect on colorectal and esophageal cancer, with smaller effects on several other common cancers.